+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
ID07788456

Evaluating Multi-Target Sequential Combination Therapy Using Corticosteroids and Thrombopoietin Receptor Agonists in Adults with Newly Diagnosed Primary Immune Thrombocytopenia

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-08-26

38

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are exploring a treatment approach for adults newly diagnosed with primary immune thrombocytopenia ITP, a condition characterized by a low platelet count. This prospective, single-arm, multicenter study will enroll 38 patients to evaluate the safety and effectiveness of combining standard-dose corticosteroids with thrombopoietin receptor agonists TPO-RA as initial therapy. The study also investigates a sequential multitarget combination strategy for patients who do not respond adequately to the initial treatment. During the core treatment phase lasting 12 weeks, patients will receive corticosteroids tapered off within 8 weeks alongside continuous TPO-RA therapy. For those with treatment failure after 2 weeks, the ongoing TPO-RA will be combined with either rituximab or an anti-CD38 monoclonal antibody as sequential combination therapy. Following this, during a 24-week follow-up and exploratory treatment phase, patients may receive switched TPO-RA combined with rituximab, anti-CD38 monoclonal antibody, or both, depending on prior treatments. The study concludes with a 4-week safety follow-up. Participants will undergo regular assessments of platelet counts, bleeding scores, and quality of life using questionnaires like the ITP-PAQ and SF-36. Researchers will monitor responses at multiple time points, including early response at 1 week and overall response at 12 weeks, with the primary outcome being the sustained response rate between weeks 13 and 36. Safety monitoring continues through the safety follow-up phase, with total participation spanning approximately 40 weeks.

CONDITIONS

Brief Title

Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Research Team

X

Xiaofan Liu

R

Rongfeng Fu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here